Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial

Fig. 2

Summary of patient-reported HAQ outcomes during and after pegloticase + methotrexate treatment (light blue bar; 52 weeks in 8 patients, 24 weeks in 2 patients; A). Patient and physician Global Assessments of Gout are also shown (B). Data represent mean values and error bars represent standard error. Weeks 64 and 76 represent the 3- and 6-month post-treatment follow-up visits, respectively. Part A reproduced from Annals of the Rheumatic Diseases 80 (Suppl 1) 2021 with permission from BMJ Publishing Group Ltd

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us